Expansion of human Vα24+ NKT cells by repeated stimulation with KRN7000

Journal of Immunological Methods

Volumn 285, Issue 2, 2004, Pages 197-214

  Rogers, Paul R ^a   Matsumoto, Atsushi ^a   Naidenko, Olga ^b,d   Kronenberg, Mitchell ^b   Mikayama, Toshifumi ^c   Kato, Shinichiro ^a  

^a Gemini Science   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c KIRIN BREWERY CO LTD   (Japan)

^d WASHINGTON UNIVERSITY   (United States)

Author keywords

Expansion; Galactosylceramide; Immunotherapy; KRN7000; Natural killer T cell; V 24

Indexed keywords

1 O (ALPHA GALACTOPYRANOSYL) 2 HEXACOSANOYLAMINO 1,3,4 OCTADECANETRIOL; CD4 ANTIGEN; INTERLEUKIN 2; CD8 ANTIGEN; GALACTOSYLCERAMIDE; GROWTH PROMOTOR; IMMUNOLOGICAL ADJUVANT; LYMPHOCYTE ANTIGEN RECEPTOR; RECOMBINANT PROTEIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; ERYTHROLEUKEMIA; HISTIOCYTE; HUMAN; HUMAN CELL; LYMPHOMA; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; TARGET CELL; CELL CULTURE; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; LEUKEMIA CELL LINE; LYMPHOCYTE ACTIVATION; METABOLISM;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD4; ANTIGENS, CD8; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; GROWTH SUBSTANCES; HUMANS; INTERLEUKIN-2; JURKAT CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT PROTEINS;

EID: 1242351228     PISSN: 00221759     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jim.2003.12.003     Document Type: Article

References (80)

1. Akutsu Y., Nakayama T., Harada M., Kawano T., Motohashi S., Shimizu E., Ito T., Kamada N., Saito T., Matsubara H., Miyazawa Y., Ochiai T., Taniguchi M. Expansion of lung Valpha14 NKT cells by administration of alpha- galactosylceramide-pulsed dendritic cells. Jpn. J. Cancer Res. 93:2002;397.
2. + T lymphocytes. Science. 268:1995;863.
3. Bendelac A., Rivera M.N., Park S.H., Roark J.H. Mouse CD1-specific NK1 T cells: development, specificity and function. Annu. Rev. Immunol. 15:1997;535.
4. Benlagha K., Weiss A., Beavis A., Teyton L., Bendelac A. In vivo identification of glycolipid antigen-specific T cells using fluorescent CD1d tetramers. J. Exp. Med. 191:2000;1895.
5. Blumberg R.S., Terhorst C., Bleicher P., McDermott F.V., Allan C.H., Landau S.B., Trier J.S., Balk S.P. Expression of a non polymorphic MHC class I-like molecule, CD1d, by human intestinal epithelial cells. J. Immunol. 147:1991;2518.
6. Bonish B., Jullien D., Dutronc Y., Bei Huang B., Modlin R., Spada F.M., Porcelli S.A., Nickoloff B.J. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-γ production by NK-T cells. J. Immunol. 165:2000;4076.
7. Brossay L., Chioda M.C., Burdin N., Koezuka Y., Casorati G., Dellabona P., Kronenberg M. CD1d mediated recognition of an alpha-galactosylceramide by NKT cells is highly conserved through mammalian evolution. J. Exp. Med. 188:1998;1521.
8. Burdin N., Brossay L., Koezuka Y., Smiley S.T., Grusby M.J., Gui M., Taniguchi M., Hayakawa K., Kronenberg M. Selective ability of mouse CD1 to present glycolipids: α-galactosylceramide specifically activates Vα14 NKT lymphocytes. J. Immunol. 161:1998;3271.
9. - T cells in transgenic mice. J. Immunol. 170:2003;2390.
10. Carnaud C., Lee D., Donnars O., Park S.H., Beavis A., Koezuka Y., Bendelac A. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163:1999;4647.
11. Davodeau F., Peyrat M.-A., Necker A., Dominici R., Blanchard F., Leget C., Gaschet J., Costa P., Jacques Y., Godard A., Vie H., Poggi A., Romagne F., Bonneville M. Close phenotypic and functional similarities between human and murine αβ T cells expressing invariant TCR α-chains. J. Immunol. 158:1997;5603.
12. - T cells. J. Exp. Med. 180:1994;1171.
13. Dhodapkar M.V., Geller M.D., Chang D.H., Shimizu K., Fujii S.-I., Dhodapkar K.M., Krasovsky J. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J. Exp. Med. 197:2003;1667.
14. Eberl B., MacDonald H.R. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells. Eur. J. Immunol. 30:2000;985.
15. - T cells. J. Exp. Med. 186:1997;109.
16. Exley M., Garcia J., Wilson S.B., Spada F., Gerdes D., Tahir S.M.A., Patton K.T., Blumberg R.S., Porcelli S., Chott A., Balk S.P. CD1d structure and regulation on human thymocytes, peripheral blood T cells, B cells and monocytes. Immunology. 100:2000;37.
17. Fujii S., Shimizu K., Kronenberg M., Steinman R.M. Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs. Nat. Immunol. 3:2002;867.
18. + natural killer T cells using alpha-galactosylceramide-pulsed dendritic cells. J. Immunol. Methods. 272:2003;147.
19. Giaccone G., Punt C.J., Ando Y., Ruijter R., Nishi N., Peters M., von Blomberg B.M., Scheper R.J., Van Der Vliet H.J., Van den Eertwegh A.J., Roelvink M., Beijnen J., Zwierzina H., Pinedo H.M. A phase I study of the natural killer T-cell ligand alpha-galactosylceramide (KRN7000) in patients with solid tumors. Clin. Cancer Res. 8:2002;3702.
20. Gumperz J.E., Miyake S., Yamamura T., Brenner M.B. Functionally distinct subsets of CD1d-restricted natural killer T cells revealed by CD1d tetramer staining. J. Exp. Med. 195:2002;625.
21. + NKT cells against normal and malignant hematological cells in vitro: a comparative study with NK cells or OKT3 activated T lymphocytes or with adult peripheral blood NKT cells. Cancer Immunol. Immunother. 51:2002;1.
22. Hayakawa Y., Takeda K., Yagita H., Kakuta S., Iwakura Y., Van Kaer L., Saiki I., Okumura K. Critical contribution of IFN-gamma and NK cells, but not perforin-mediated cytotoxicity, to anti-metastatic effect of alpha-galactosylceramide. Eur. J. Immunol. 31:2001;1720.
23. Hong S., Wilson M.T., Serizawa I., Wu L., Singh N., Naidenko O.V., Miura T., Haba T., Scherer D.C., Wei J., Kronenberg M., Koezuka Y., Van Kaer L. The natural killer T-cell ligand alpha-galactosylceramide prevents autoimmune diabetes in non-obese diabetic mice. Nat. Med. 7:2001;1052.
24. + NK cells in vitro. J. Immunol. 165:2000;1659.
25. Jacobson E.L., Pilaro F., Smith K.A. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity. Proc. Natl. Acad. Sci. U. S. A. 93:1996;10405.
26. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Motoki K., Ueno H., Nakagawa R., Sato H., Kondo E., Koseki H., Taniguchi M. CD1d-restricted and TCR-mediated activation of Vα14 NK T cells by glycosylceramides. Science. 278:1997;1626.
27. Kawano T., Cui J., Koezuka Y., Toura I., Kaneko Y., Sato H., Kondo E., Harada M., Koseki H., Nakayama T., Tanaka Y., Taniguchi M. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells. Proc. Natl. Acad. Sci. 95:1998;5690.
28. Kawano T., Nakayama T., Kamada N., Kaneko Y., Harada M., Ogura N., Akutsu Y., Motohashi S., Iizasa T., Endo H., Fujusawa T., Shinkai H., Taniguchi M. Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells. Cancer Res. 59:1999;102.
29. Kita H., Naidenko O., Kronenberg M., Ansari A.A., Rogers P., He X.-S., Koning F., Mikayama T., van de Water J., Coppel R.L., Kaplan M., Gershwin M.E. Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. Gastroenterology. 123:2002;1031.
30. Kobayashi E., Motoki K., Uchida T., Fukushima H., Koezuka Y. KRN7000, a novel immunomodulator, and its antitumor activities. Oncol. Res. 7:1995;529.
31. Lanier L.L., Chang C., Phillips J.H. Human NKR-P1A. A disulfide-linked homodimer of the C-type lectin superfamily expressed by a subset of NK and T lymphocytes. J. Immunol. 153:1994;2417.
32. Lee P.T., Benlagha K., Teyton L., Bendelac A. Distinct functional lineages of human V (alpha)24 natural killer T cells. J. Exp. Med. 195:2002;637.
33. Lucas M., Gadola S., Meier U., Young N.T., Harcourt G., Karadimitris A., Coumi N., Brown D., Dusheiko G., Cerundolo V., Klenerman P. Frequency and phenotype of circulating Valpha24/Vbeta11 double-positive natural killer T cells during hepatitis C virus infection. J. Virol. 77:2003;2251.
34. Magnan A., Mely L., Prato S., Vervloet D., Romagne F., Camilla C., Necker A., Casano B., Montero-Jullian F., Fert V., Malissen B., Bongrand P. Relationships between natural T cells, atopy, IgE levels, and IL-4 production. Allergy. 55:2000;286.
35. Mars L.T., Laloux V., Goude K., Desbois S., Saoudi A., Van Kaer L., Lassmann H., Herbelin A., Lehuen A., Liblau R.S. Cutting edge: V alpha 14-J alpha 281 NKT cells naturally regulate experimental autoimmune encephalomyelitis in nonobese diabetic mice. J. Immunol. 168:2002;6007.
36. Matsuda J.L., Gapin L., Sidobre S., Kieper W.C., Tan J.T., Ceredig R., Surh C.D., Kronenberg M. Homeostasis of V alpha 14i NKT cells. Nat. Immunol. 3:2002;966.
37. Matsuda J.L., Naidenko O.V., Gapin L., Nakayama T., Taniguchi M., Wang C.-R., Koezuka Y., Kronenberg M. Tracking the response of natural killer T cells to a glycolipid antigen using CD1d tetramers. J. Exp. Med. 192:2000;741.
38. Metelitsa L.S., Naidenko O.V., Kant A., Wu H.-W., Loza M.J., Perussia B., Kronenberg M., Seeger R.C. Human NKT cells mediate antitumor cytotoxicity directly by recognizing target cell CD1d with bound ligand or indirectly by producing IL-2 to activate NK cells. J. Immunol. 167:2001;3114.
39. Metelitsa L.S., Weinberg K.I., Emanuel P.D., Seeger R.C. Expression of CD1d by myelomonocytic leukemias provides a target for cytotoxic NKT cells. Leukemia. 17:2003;1068.
40. Morita M., Motoki K., Akimoto K., Natori T., Sakai T., Sawa E., Yamaji K., Koezuka Y., Kobayashi E., Fukushima H. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice. J. Med. Chem. 38:1995;2176.
41. Motoki K., Maeda K., Ueno H., Kobayashi E., Uchida T., Fukushima H., Koezuka Y. Antitumor activities of combined treatment with a novel immunomodulator, (2S,3S,4R)-1-O-(alpha-D-galactopyranosyl)-2-(N- hexacosanoylamino)-1,3,4-octadecanetriol (KRN7000), and radiotherapy in tumor-bearing mice. Oncol. Res. 8:1996;155.
42. Nakagawa R., Motoki K., Nakamura H., Ueno H., Iijima R., Yamauchi A., Tsuyuki S., Inamoto T., Koezuka Y. Antitumor activity of alpha- galactosylceramide, KRN7000, in mice with EL-4 hepatic metastasis and its cytokine production. Oncol. Res. 10:1998;561.
43. Nakagawa R., Motoki K., Ueno H., Iijima R., Nakamura H., Kobayashi E., Shimosaka A., Koezuka Y. Treatment of hepatic metastasis of the colon26 adenocarcinoma with an alpha-galactosylceramide, KRN7000. Cancer Res. 58:1998;1202.
44. Nakagawa R., Serizawa I., Motoki K., Sato M., Ueno H., Iijima R., Nakamura H., Shimosaka A., Koezuka Y. Antitumor activity of alpha- galactosylceramide, KRN7000, in mice with the melanoma B16 hepatic metastasis and immunohistological study of tumor infiltrating cells. Oncol. Res. 12:2000;51.
45. Nakagawa R., Nagafune I., Tazunoki Y., Ehara H., Tomura H., Iijima R., Motoki K., Kamishohara M., Seki S. Mechanisms of the antimetastatic effect in the liver and of the hepatocyte injury induced by α-galactosylceramide in mice. J. Immunol. 166:2001;6578.
46. + natural killer T cells activated by alpha- galactosylceramide (KRN7000) have cytotoxic anti-tumour activity through mechanisms distinct from T cells and natural killer cells. Immunology. 99:2000;229.
47. Nieda M., Nicol A., Koezuka Y., Kikuchi A., Takahashi T., Nakamura H., Furukawa H., Yabe T., Ishikawa Y., Tadokoro K., Juji T. Activation of human Valpha24 NKT cells by alpha-glycosylceramide in a CD1d-restricted and Valpha24 TCR-mediated manner. Hum. Immunol. 60:1999;10.
48. + Valpha24 natural killer T cells expressing CD40L. Immunology. 102:2001;137.
49. Nieda M., Nicol A., Koezuka Y., Kikuchi A., Lapteva N., Tanaka Y., Tokunaga K., Suzuki K., Kayagaki N., Yagita H., Hirai H., Juji T. TRAIL expression by activated human CD4(+)V alpha 24NKT cells induces in vitro and in vivo apoptosis of human acute myeloid leukemia cells. Blood. 97:2001;2067.
50. + NKT cells in human subjects results in highly co-ordinated secondary activation of acquired and innate immunity. Blood. 103:2004;383.
51. + T cells in vitro. Hum. Immunol. 61:2000;357.
52. + T cells and rapid elimination of effector cells by apoptosis. Eur. J. Immunol. 28:1998;3448.
53. Oishi Y., Sumida T., Sakamoto A., Kita Y., Kurasawa K., Nawata Y., Takabayashi K., Takahashi H., Yoshida S., Taniguchi M., Saito Y., Iwamoto I. Selective reduction and recovery of invariant Valpha24JalphaQ T cell receptor T cells in correlation with disease activity in patients with systemic lupus erythematosus. J. Rheumatol. 28:2001;275.
54. + NKT cells expand following administration of alpha-galactosylceramide-pulsed dendritic cells. Vox Sang. 83:2002;250.
55. Porcelli S.A., Modlin R.L. The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids. Annu. Rev. Immunol. 17:1999;297.
56. - α/β T cells demonstrates preferential use of several Vβ genes and an invariant TCR chain. J. Exp. Med. 178:1993;1.
57. Prussin C., Foster B. TCR Vα24 and Vβ11 coexpression defines a human NK1 T cell analog containing a unique Th0 subpopulation. J. Immunol. 159:1997;5862.
58. Reinhardt C., Melms A. Elevated frequencies of natural killer T lymphocytes in myasthenia gravis. Neurology. 52:1999;1485.
59. Sandberg J.K., Fast N.M., Palacios E.H., Fennelly G., Dobroszycki J., Palumbo P., Wiznia A., Grant R.M., Bhardwaj N., Rosenberg M.G., Nixon D.F. Selective loss of innate CD4(+) Valpha24 natural killer T cells in human immunodeficiency virus infection. J. Virol. 76:2002;7528.
60. Sandberg J.K., Bhardwaj N., Nixon D.F. Dominant effector memory characteristics, capacity for dynamic adaptive expansion, and sex bias in the innate Valpha24 NKT cell compartment. Eur. J. Immunol. 33:2003;588.
61. Sharif S., Arreaza G.A., Zucker P., Mi Q.S., Sondhi J., Naidenko O.V., Kronenberg M., Koezuka Y., Delovitch T.L., Gombert J.M., Leite-De-Moraes M., Gouarin C., Zhu R., Hameg A., Nakayama T., Taniguchi M., Lepault F., Lehuen A., Bach J.F., Herbelin A. Activation of natural killer T cells by alpha-galactosylceramide prevents the onset and recurrence of autoimmune Type I diabetes. Nat. Med. 7:2001;1057.
62. Shin T., Nakayama T., Akutsu Y., Motohashi S., Shibata Y., Harada M., Kamada N., Shimizu C., Shimizu E., Saito A., Ochiai T., Taniguchi M. Inhibition of tumor metastasis by adoptive transfer of IL-12-activated Vα14 NKT cells. Int. J. Cancer. 91:2001;523.
63. Singh A.K., Wilson M.T., Hong S., Olivares-Villagomez D., Du C., Stanic A.K., Joyce S., Sriram S., Koezuka Y., Van Kaer L. Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis. J. Exp. Med. 194:2001;1801.
64. Spada F., Koezuka Y., Porcelli S.A. CD1d-restricted recognition of synthetic glycolipid antigens by human NK T cells. J. Exp. Med. 188:1998;1529.
65. Spada F.M., Borriello F., Sugita M., Watts G.F.M., Koezuka Y., Porcelli S.A. Low expression level but potent antigen presenting function of CD1d on monocyte lineage cells. Eur. J. Immunol. 30:2000;3468.
66. Sumida T., Sakamoto A., Murata H., Makino Y., Takahashi H., Yoshida S., Nishioka K., Iwamoto I., Taniguchi M. Selective reduction of T cells bearing invariant V alpha 24 J alpha Q antigen receptor in patients with systemic sclerosis. J. Exp. Med. 182:1995;1163.
67. Tahir S.M.A., Cheng O., Shaulov A., Koezuka Y., Bubley G.J., Wilson S.B., Balk S.P., Exley M.A. Loss of IFN-γ production by invariant NK T cells in advanced cancer. J. Immunol. 167:2001;4046.
68. + NKT cells activated by alpha-glycosylceramide-pulsed monocyte-derived dendritic cells. J. Immunol. 164:2000;4458.
69. + natural killer T-cell responses against T-acute lymphoblastic leukemia cells: implications for immunotherapy. Br. J. Haematol. 122:2003;231.
70. Toura I., Kawano T., Akutsu Y., Nakayama T., Ochiai T., Taniguchi M. Cutting edge: inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide. J. Immunol. 163:1999;2387.
71. + T cells. Immunology. 98:1999;557.
72. van der Vliet H.J., Nishi N., Koezuka Y., von Blomberg B.M., van den Eertwegh A.J., Porcelli S.A., Pinedo H.M., Scheper R.J., Giaccone G. Potent expansion of human natural killer T cells using alpha-galactosylceramide (KRN7000)-loaded monocyte-derived dendritic cells, cultured in the presence of IL-7 and IL-15. J. Immunol. Methods. 247:2001;61.
73. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage. Clin. Immunol. 100:2001;144.
74. + NKT cells during HIV type 1 infection. J. Immunol. 168:2002;1490.
75. Wang B., Geng Y.B., Wang C.R. CD1-restricted NKT cells protect nonobese diabetic mice from developing diabetes. J. Exp. Med. 194:2001;313.
76. Wilson S.B., Delovitch T.L. Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity. Nat. Rev., Immunol. 3:2003;211.
77. Wilson S.B., Kent S.C., Patton K.T., Orban T., Jackson R.A., Exley M., Porcelli S., Schatz D.A., Atkinson M.A., Balk S.P., Strominger J.L., Hafler D.A. Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes. Nature. 391:1998;177.
78. Wu D.Y., Segal N.H., Sidobre S., Kronenberg M., Chapman P.B. Cross-presentation of disialoganglioside GD3 to natural killer T cells. J. Exp. Med. 198:2003;173.
79. Yamaguchi Y., Motoki K., Ueno H., Maeda K., Kobayashi E., Inoue H., Fukushima H., Koezuka Y. Enhancing effects of (2S,3S,4R)-1-O-(alpha-D- galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol (KRN7000) on antigen-presenting function of antigen-presenting cells and antimetastatic activity of KRN7000-pretreated antigen-presenting cells. Oncol. Res. 8:1996;399.
80. Yanagisawa K., Seino K., Ishikawa Y., Nozue M., Todoroki T., Fukao K. Impaired proliferative response of Vα24 NKT cells from cancer patients against α-galactosylceramide. J. Immunol. 168:2002;6494.